Clinical Research Directory

Inclusion Criteria: * Aged 18 to 80 years (inclusive) at the time of informed consent * Histologically or cytologically confirmed B cell neoplasm. * Phase 1: Relapsed or refractory disease after at least two prior systemic therapy. * Measurable or evaluable disease at enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Adequate organ and bone marrow function * Life expectancy of ≥ 3 months Exclusion Criteria: * Prior treatment with bispecific antibodies targeting both CD20 and CD3 * Prior treatment with antibodies targeting both PD-1/PD-L1, PD-(L)1/VEGF(R) or PD-(L)1/TGF-β * Eligible for high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) * Known central nervous system (CNS) involvement by lymphoma * Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks * Chemotherapy and other non-investigational antineoplastic agents within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration